Clinical Trial Update: Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers [Phase 3]

View source ↗

Summary

A Phase 3 safety and efficacy study of Engensis (VM202) for chronic non-healing diabetic foot ulcers was terminated, with results posted in February 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer

Drugs mentioned

• Engensis (VM202)

Snippet

Sponsor: Helixmith Co., Ltd. | Conditions: Foot Ulcer, Diabetic | Phase 3 | Status: TERMINATED | Results posted: 2023-02-22